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OBJECTIVE — To test the validity of the Framingham, Systematic Coronary Risk Evaluation
(SCORE), and UK Prospective Diabetes Study (UKPDS) risk function in the prediction of risk of
coronaryheartdisease(CHD)inpopulationswithnormalglucosetolerance(NGT),intermediate
hyperglycemia, and type 2 diabetes.
RESEARCH DESIGN AND METHODS — Calibration and discrimination of the three
prediction models were tested using prospective data for 1,482 Caucasian men and women,
50–75 years of age, who participated in the Hoorn Study. All analyses were stratiﬁed by glucose
status.
RESULTS — During 10 years of follow-up, a total of 197 CHD events, of which 43 were fatal,
were observed in this population, with the highest percentage of ﬁrst CHD events in the diabetic
group. The Framingham and UKPDS prediction models overestimated the risk of ﬁrst CHD
event in all glucose tolerance groups. Overall, the prediction models had a low to moderate
discriminatory capacity. The SCORE risk function was the best predictor of fatal CHD events in
the group with NGT (area under the receiver operating characteristic curve 0.79 [95% CI
0.70–0.87]), whereas the UKPDS performed better in the intermediate hyperglycemia group
(0.84 [0.74–0.94]) in the estimation of fatal CHD risk. After exclusion of known diabetic
patients, all prediction models had a higher discriminatory ability in the group with diabetes.
CONCLUSIONS — The use of the Framingham function for prediction of the ﬁrst CHD
eventislikelytooverestimateanindividual’sabsoluteCHDrisk.InCHDprevention,application
of the SCORE and UKPDS functions might be useful in the absence of a more valid tool.
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C
oronary heart disease (CHD) is a
leading cause of mortality in the
world, and projections show that
this will still be the case in 2025 (1).
Awareness of the public health relevance
of the disease has brought about an in-
creasing body of evidence on interven-
tions that can effectively reduce the
incidenceofCHD(2,3).Akeycomponent
for effective targeting of these interventions
istheassessmentofanindividual’sabsolute
risk of developing CHD within a deﬁned
time period.
Risk of CHD can be assessed using
several methods that combine values for
different risk factors to produce a quanti-
tative risk estimate. These risk calculation
algorithms are derived from long-term
prospective cohort studies. The most
widely used models are based on data
from the Framingham Heart Study for
ﬁrst CHD event (4,5). More recently, the
Systematic Coronary Risk Evaluation
(SCORE) Project developed a risk func-
tion for estimation of fatal CHD derived
fromEuropeandata(6).TheUKProspec-
tive Diabetes Study (UKPDS) Group de-
veloped a diabetes-speciﬁc algorithm for
ﬁrst CHD event, acknowledging the fact
that patients with type 2 diabetes have an
increased risk for CHD (7). Because of
this increased risk for CHD, models de-
rived from diabetic populations are ex-
pected to offer better predictive accuracy
of CHD morbidity and mortality in indi-
viduals with diabetes than general popu-
lation–based models.
Anaprioriassessmentoftheaccuracy
and validity of a risk algorithm should be
performed when one is applying it to a
population different from the one in
which it was developed. Thus, the perfor-
mance of the Framingham, SCORE, and
UKPDS risk algorithms in predicting
CHD events in both U.S. and European
populations has been reported (8–14).
The accuracy of these algorithms has
not been prospectively evaluated in a
population at high risk for developing
diabetes, such as individuals with inter-
mediate hyperglycemia, who have been
identiﬁed as having an increased CHD
risk compared with that of normoglyce-
mic individuals or have even been
thought to have the same risk as indi-
viduals with established diabetes (15).
The purpose of the present study was to
validate and compare results from the
Framingham, SCORE, and UKPDS risk
functions in predicting CHD risk of in-
dividualswithnormalglucosetolerance
(NGT), intermediate hyperglycemia
(i.e., impaired glucose tolerance and/or
impaired fasting glucose), and diabetes,
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Hoorn Study cohort.
RESEARCH DESIGN AND
METHODS— The Hoorn Study is a
population-based cohort study of glucose
metabolism of 2,484 Dutch Caucasian
men and women, aged 50–75 years at
studyinitiationin1989.Thestudydesign
and population have been described in
detail elsewhere (16).
For the current study, we included
participants with NGT (n  1,791), par-
ticipants with intermediate hyperglyce-
mia(n423),andparticipantswithtype
2 diabetes (n  255) at baseline. After
exclusion of individuals with a previous
history of cardiovascular disease at base-
line (NGT n  294, intermediate hyper-
glycemia n  99, and diabetes n  77)
and of individuals with missing values for
anyofthepredictorvariables(NGTn8,
intermediate hyperglycemia n  3, and
diabetes n  10) or outcome variables
(NGT n  364, intermediate hyperglyce-
mia n  89, and diabetes n  43), 1,125
individuals with NGT, 232 individuals
with intermediate hyperglycemia, and
125 individuals with diabetes remained
for the current analyses. All participants
provided written informed consent. Eth-
ics approval for the study was obtained
from the Ethics Review Committee of
the VU University Medical Center
Amsterdam.
Measurements
According to baseline levels of fasting
plasma glucose and 2 h after an oral glu-
cose tolerance test, participants were
classiﬁedintoNGT,intermediatehyper-
glycemia, or diabetes groups, which were
deﬁned according to the 2006 criteria of
the World Health Organization (17). In-
dividuals who were already being treated
for diabetes with insulin, oral hypoglyce-
micagents,oraphysician-prescribeddiet
were categorized as known diabetic sub-
jects, irrespective of their glucose levels.
Weight and height were measured in
barefoot participants wearing light cloth-
ing. BMI was calculated as weight in kilo-
grams divided by the square of height in
meters. Blood pressure was measured in
a sitting position after 5 min of rest using
a random-zero sphygmomanometer
(Hawksley-Gelman, Lancing, Sussex,
U.K.). Serum total and HDL cholesterol
levels were measured using an enzymatic
technique (Boehringer-Mannheim,
Mannheim, Germany) as described else-
where (18). A1C was determined by ion-
exchange high-performance liquid
chromatography with a Modular Dia-
betes Monitoring System (Bio-Rad,
Veenendaal, the Netherlands). Informa-
tion about cigarette smoking, diabetes
duration in those with a diagnosis of dia-




Primary end points deﬁned for this
studywereCHDeventsthathadoccurred
until1January2000.Informationonfatal
and nonfatal CHD events was classiﬁed
using medical records of general practi-
tioners and the local hospital. Morbidity
and fatal events were coded according to
the ICD-9. CHD was deﬁned as fatal and




Baseline characteristics are presented as
means  SD, median (interquartile
range) in case of a skewed distribution, or
percentages according to glucose status
group. Estimated 10-year ﬁrst CHD risk
was calculated for each participant using
the Framingham (5) and UKPDS (7) algo-
rithms. Estimated 10-year risk of fatal CHD
was calculated by means of the SCORE risk
function developed for the low-risk re-
gionofEurope.Toestimatetheriskinthe
diabetic subgroup, the predicted risk by
theSCOREalgorithmwasmultipliedby2
for men and by 4 for women, as recom-
mended by Conroy et al. (6).
The predictive accuracy of the three
risk functions was estimated using cali-
bration (the ability to predict the number
of observed events during follow-up) and
discrimination appraisals (the ability to
distinguish between those who experi-
ence a CHD event during follow-up from
those who do not). These two approaches
have been described in detail previously
(19).
Calibration of the model was visually
checked by plotting the predicted proba-
bilities estimated by the prediction mod-
elsagainsttheobservedproportionofﬁrst
CHD events (Framingham and UKPDS)
and fatal CHD events (SCORE). Partici-
pants were grouped into quintiles of
predicted CHD risk within 10 years of
follow-up.Plotswerecreatedforthethree
glucose status subgroups. The discrimi-
natory ability of the models was assessed
by calculating the area under the receiver
operating characteristic curve (AUROC)
usingthe10-yearriskestimatespredicted
by the three models. The discriminatory
power of models is graded as low for an
AUROC between 0.5 and 0.7, moderate
between 0.7 and 0.9, and high if 0.9
(20).
Because the UKPDS risk function is
derived from a cohort of patients with
newly diagnosed diabetes and the Fra-
mingham and SCORE functions do not
include information about diabetes dura-
tion, sensitivity analyses were carried out
to test the discriminatory ability of the
risk algorithms in predicting ﬁrst or fatal
CHD event in individuals with screening-
detected diabetes only. Furthermore, be-
cause family history of myocardial
infarction is a strong predictor of the in-
cidence of CHD and is part of usual risk
assessment in general practice (21), we
tested whether the addition of family
history of myocardial infarction to the
prediction formulas improved risk esti-
mation of the ﬁrst CHD event. Improve-
ments in AUROCs and reclassiﬁcation
improvements were examined and tested
for signiﬁcance using methods described
previously (22,23). All statistical analyses
wereperformedusingSPSS15.0forWin-
dows (SPSS, Chicago, IL).
RESULTS— Table 1 presents baseline
and end point characteristics stratiﬁed by
glucose status subgroup. Antihyperten-
sive and lipid-lowering medication use
was highest among diabetic subjects. A
total of 197 ﬁrst CHD events, of which 43
were fatal, were observed in this popula-
tion. A higher percentage of ﬁrst CHD
events occurred in participants with dia-
betes compared with participants catego-
rized in the NGT or intermediate
hyperglycemia subgroup.
Figure 1 depicts the calibration plots
for the prediction of ﬁrst and fatal CHD
events. The Framingham and UKPDS
predictionmodelsshowedanoverestima-
tion of the risk of the ﬁrst CHD event,
mainlyintheupperquintilesofpredicted
risk in the NGT, the intermediate hyper-
glycemia, and the diabetes subgroup.
The estimation of fatal CHD events by the
SCORE algorithm was fair in both the
NGT and intermediate hyperglycemia
group but less precise in the diabetic
group.
The discriminatory results from the
three models, applied to the Hoorn sub-
populations, are presented in Table 2,
showing the AUROCs and 95% CIs. The
Framingham prediction formula showed
the lowest AUROCs among all glucose
status groups in estimation of ﬁrst CHD
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the highest area under the curve when
fatal CHD risk in the NGT subgroup
(AUROC 0.79 [95% CI 0.70–0.87]) and
in the diabetic subgroup (0.74 [0.56–
0.93]) was estimated. For the intermedi-
ate hyperglycemia group, moderate
discriminatory ability (AUROC 0.70)
was only seen for Framingham (0.76
[0.65–0.88]) and UKPDS (0.84 [0.74 –
0.94]) for fatal CHD risk. In the diabetic
subgroup, all prediction models had low
discriminatory ability for estimating the
risk of ﬁrst CHD event, whereas SCORE
and UKPDS had moderate ability to iden-
tify individuals with a high risk for a fatal
CHD event. The UKPDS risk model, de-
rived from a diabetic population, showed
a slightly higher area under the curve in a
populationwithNGT(0.71[0.66–0.75])
and in the population with intermediate
hyperglycemia (0.70 [0.60–0.80]) com-
pared with the diabetic population (0.66
[0.56–0.78]). Overall, all prediction
models showed better discrimination
when a fatal CHD event was used as the
predicted outcome.
When the discriminatory ability of
the three risk functions to estimate risk
of a ﬁrst CHD event in individuals with
screening-detected diabetes was ana-
lyzed, all risk functions showed higher
areas under the curve in this group com-
pared with those in the group in which in-
dividuals with screening-detected diabetes
and known diabetes were combined (Fra-
mingham 0.74 [95% CI 0.59–0.89],
SCORE 0.79 [0.66–0.92], and UKPDS
0.75 [0.63–0.87]). Similar results were
seen for estimations of a fatal CHD event
(Framingham 0.73 [0.50–0.95], SCORE
0.82[0.67–0.97],andUKPDS0.83[0.68–
0.97]). The addition of family history of
myocardial infarction slightly improved
most risk algorithms in prediction of the
risk of a ﬁrst CHD event although the
changes were not statistically signiﬁcant.
CONCLUSIONS— In this study, we
compared the performance of two risk
functions designed for the general popu-
lationandonediabetes-speciﬁcriskfunc-
tion in predicting nonfatal and/or fatal
CHD risk in a general, pre-diabetic, and
diabetic population during 10 years of
follow-up. With respect to the agreement
between the predicted and observed esti-
mates, the Framingham and UKPDS risk
function overall overestimated the actual
observed CHD incidence rate in the three
subgroups. Regarding the risk of ﬁrst
CHD,theFraminghamalgorithmhadlow
abilitytodiscriminateinallsubgroupsex-
cept for the group consisting of patients
with screening-detected diabetes in
whom the discriminatory ability was
moderate. The UKPDS function had
moderate ability to identify those with
highriskforaﬁrstCHDeventintheNGT
and intermediate hyperglycemia groups
and in patients with screening-detected
diabetes but low ability in the group in
which patients with screening-detected
and known diabetes were combined. The
SCOREalgorithmforthepredictionoffa-
tal CHD has a moderate ability in all sub-
groups. Although the Framingham and
UKPDS risk functions were designed to
estimate ﬁrst CHD in the general popula-
tion and the diabetic population, respec-
tively, both functions performed better in
estimatingfatalCHDthantheSCORErisk
function for fatal CHD with the highest
discriminatory ability being observed for
the UKPDS risk function in the interme-
diate hyperglycemia group.
The results of our study do not sup-
port the ﬁndings in previous studies in
which the CHD risk in a population with
diabetes was underestimated by the Fra-
mingham (10,14) and UKPDS risk func-
tions (12). Previous research also showed
an overestimation of CHD risk predicted
by the UKPDS risk function during 5
years of follow-up (24), the SCORE risk
function during 10 years of follow-up
(11), and the Framingham risk function
in European populations (8,9). Recently,
the performance of the Framingham and
UKPDS risk functions for estimation of
cardiovascular disease risk has been
tested, and both functions were found to
overestimate the cardiovascular disease
risk and to be moderately effective in a
normoglycemic, pre-diabetic, and dia-
betic population (25). These results are
comparable to the predictive accuracy of
the CHD risk functions in our study de-
spite the different criteria used to deﬁne
the three glucose status groups.
Some possible reasons for the overes-
timation of CHD risk by the Framingham
and UKPDS prediction models in our
study population can be suggested. Pre-
diction of the risk of CHD, calculated by
the Framingham function, might result in










n 1,125 232 85 40
Age (years) 60.3  7.1 63.2  7.3 64.5  6.9 64.9  7.0
Men (%) 45.2 47.2 54.0 46.3
BMI (kg/m
2) 25.9  3.1 27.5  3.6 28.6  4.1 27.6  4.2
Systolic blood pressure
(mmHg) 131.6  19.2 143.3  20.4 148.3  21.3 143.2  21.2
Diastolic blood pressure
(mmHg) 81.4  10.3 84  9.8 85.8  11.7 83.2  10.4
Total cholesterol (mmol/l) 6.6  1.2 6.7  1.0 6.7  1.4 6.5  1.4
HDL cholesterol (mmol/l) 1.4  0.4 1.3  0.3 1.2  0.3 1.2  0.3
LDL cholesterol (mmol/l) 4.6  1.1 4.6  1.0 4.5  1.2 4.2  0.9
A1C (%) 5.3  0.5 6.7  1.0 6.4  1.7 7.6  1.6
Diabetes duration (years) — — — 6.1 (2.0–11.2)
Current smokers (%) 32.6 24.5 25.3 17.1
Antihypertensive
medication (%) 10.0 19.3 25.3 29.3
Lipid-lowering
medication (%) 0.7 0.4 1.1 2.4
Family history of
myocardial infarction 185 (16.5) 31 (13.4) 15 (17.6) 4 (10)
First CHD 108 (9.6) 24 (10.3) 16 (18.8) 12 (30.0)
Fatal CHD 27 (2.4) 6 (2.6) 8 (9.4) 2 (5)
Incidence rate*
First CHD 1,170.6 1,310.9 2,532.8 4,470.9
Fatal CHD 292.6 327.7 1,266.4 745.2
Values are presented as means  SD, median (interquartile range), absolute numbers, or n (%). *The
incidence rate is expressed as the number of new cases per 100,000 person-years.
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tion well treated for cardiovascular risk
factors,asisthecasewiththeHoornpop-
ulation. This phenomenon may also con-
tribute to the better prediction in patients
with newly diagnosed diabetes compared
with those with known diabetes. In addi-
tion, it is suggested that risk estimation
might be more accurate in individuals
with fewer risk factors (4). Indeed, in the
current study, a larger overestimation of
the actual observed CHD events was seen
in individuals in the higher quintiles of
estimated CHD risk. Regarding the
SCORE risk function for estimating fatal
CHD events, the estimation could have
been less precise because of the small
number of observed fatal CHD events in
the current study. In addition, partici-
pants with missing information on CHD
eventswereexcluded,andaselectionbias
could have occurred. The population
usedforthecurrentstudyconsistsofCau-
casian men and women. Because perfor-
mance of the risk functions might differ
between different ethnic groups, the re-
sults of our study cannot be immediately
generalizedtopopulationsofotherethnic
origin. Furthermore, the UKPDS risk
function was based on patients with
newlydiagnoseddiabetes,andourresults
suggested better performance of the risk
algorithms when they were applied solely
to patients with newly detected diabetes.
The SCORE and Framingham risk func-
tions also showed better discriminatory
abilityinpatientswithscreening-detected
diabetes. Values of risk factors used for
the development of the UKPDS predic-
tion model were based on measurements
taken at 1 or 2 years after diagnosis of
diabetes. At that time treatment has
changed, which resulted in altered risk
proﬁles for most patients. In our diabetic
subgroup, 68% of the participants had
the diagnosis of diabetes at baseline and
risk factor levels at the baseline mea-
surementwereusedforallanalyses.The
different time of measurement could be
a reason for the overestimation of the risk
of ﬁrst CHD calculated by the UKPDS risk
engine.
In summary, we found that the use of
the Framingham function in the predic-
Figure 1—Observed and predicted incidence of ﬁrst CHD events (A–C) and fatal CHD events (D–F) in quintiles of predicted risk estimated by the
Framingham ( ), SCORE (E), and UKPDS (Œ) risk function according to glucose status group. IH, intermediate hyperglycemia; DM, type 2
diabetes.
Table 2—Discriminatory ability of the Framingham, SCORE, and UKPDS risk functions
NGT group
Intermediate
hyperglycemia group Diabetic group
First CHD
Framingham 0.68 (0.63–0.74) 0.60 (0.47–0.74) 0.63 (0.50–0.76)
SCORE 0.71 (0.66–0.76) 0.70 (0.60–0.79) 0.66 (0.54–0.79)
UKPDS 0.71 (0.66–0.75) 0.70 (0.60–0.80) 0.66 (0.56–0.78)
Fatal CHD
Framingham 0.71 (0.61–0.82) 0.76 (0.65–0.88) 0.61 (0.37–0.86)
SCORE 0.79 (0.70–0.87) 0.70 (0.50–0.89) 0.74 (0.56–0.93)
UKPDS 0.77 (0.68–0.86) 0.84 (0.74–0.94) 0.72 (0.55–0.89)
Data are AUROC (95% CI).
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in the Hoorn cohort was likely to overes-
timate an individual’s absolute CHD risk.
From a clinical perspective, this overesti-
mation may lead to improper targeting of
preventive strategies because of the large
number of patients with false-positive re-
sults who are identiﬁed for treatment.
From a health policy point of view, this
may cause incorrect allocation of health
resources. The equation might be used to
estimate potential relative reduction in
CHD risks. To aid in CHD prevention,
application of the SCORE risk function in
diabetic patients and application of the
SCORE and UKPDS risk functions in in-
dividuals with normal glucose metabo-
lism or intermediate hyperglycemia
might prove useful in the absence of a
more valid tool.
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